ImmunID makes its mark in oncology

Grenoble-based start-up ImmunID is presenting the results of clinical trials on its Lymphodivpenia biomarker at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 1 to June 5, 2012. This ground-breaking immune system biomarker can be used to maximize the efficacy of chemotherapy treatments while limiting the side effects.
The literature offers ample confirmation—including two articles in Nature—of the important role that immunology can play in treating cancer. ImmunID aims to leverage this discovery and carry out other large-scale clinical trials; the company will first lay the groundwork by raising capital and forming top-tier research partnerships.
 
Contact: npasqual@immunid.com

Facebook

Twitter